Can menopause, low adrenal precursors, and high SHBG reduce free androgen signaling?

Postmenopausal androgen decline is a complex physiological process that extends beyond simple ovarian aging, involving a dynamic interplay between ovarian, adrenal, and hepatic pathways.

Mechanistic pathways

• Ovarian and Adrenal Depletion: Menopause-related ovarian decline leads to a gradual, significant reduction in direct ovarian androgen output. Simultaneously, age-related adrenal involution decreases circulating dehydroepiandrosterone sulfate (DHEA-S)—the primary precursor required for peripheral conversion into active intracellular testosterone.
• Estrogen-Driven Hepatic SHBG Production: Estrogens stimulate hepatocyte receptors to upregulate sex hormone-binding globulin (SHBG) synthesis. This effect is highly sensitive to the route of estrogen administration; oral estrogen therapy undergoes first-pass hepatic metabolism, causing a marked 67% to over 160% increase in circulating SHBG levels.
• Adrenal Suppression: Beyond hepatic stimulation, oral estrogen therapy can suppress adrenal steroidogenesis, resulting in an approximate 23% reduction in DHEA-S levels, further limiting the available precursor pool.
• Androgen Sequestration: High circulating SHBG binds free testosterone with high affinity. The combination of increased SHBG sequestration, reduced ovarian androgen synthesis, and depleted DHEA-S precursors synergistically minimizes the fraction of bioavailable (free) testosterone, severely limiting cellular androgen signaling.

Bottom line

• Reduced free androgen signaling in postmenopause is driven by a triad of diminished ovarian output, an approximate 23% drop in adrenal precursors, and oral-estrogen-induced hepatic SHBG elevations of 67% to over 160%, which collectively sequester the remaining active androgen pool.